Cardiovascular events and mortality in chronic kidney disease (stages I-IV) Borja Quiroga, Úrsula Verdalles, Javier Reque, Soledad García de Vinuesa, Marian Goicoechea, José Luño

Effectivity and safety profile of tenapanor, a sodium-hydrogen exchanger isoform 3 inhibitor, as an innovative treatment for hyperphosphatemia in chronic kidney disease: A systematic review of clinical studies William Suciangto, Haerani Rasyid, Anastasya Angelica Vicente, Winny Suciangto

Bone mineral disorder in chronic kidney disease: Klotho and FGF23; cardiovascular implications Laura Salanova Villanueva, Carmen Sánchez González, José Antonio Sánchez Tomero, Abelardo Aguilera, Esther Ortega Junco